- Home
- CRSR vs NRIX Comparison
CRSR vs NRIX Comparison
Compare CRSR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSR
- NRIX
- Stock Information
- Founded
- CRSR 1994
- NRIX 2009
- Country
- CRSR United States
- NRIX United States
- Employees
- CRSR N/A
- NRIX N/A
- Industry
- CRSR Computer Manufacturing
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- CRSR Technology
- NRIX Health Care
- Exchange
- CRSR Nasdaq
- NRIX Nasdaq
- Market Cap
- CRSR 1.1B
- NRIX 1.1B
- IPO Year
- CRSR 2020
- NRIX 2020
- Fundamental
- Price
- CRSR $8.79
- NRIX $10.63
- Analyst Decision
- CRSR Buy
- NRIX Strong Buy
- Analyst Count
- CRSR 6
- NRIX 17
- Target Price
- CRSR $10.00
- NRIX $30.71
- AVG Volume (30 Days)
- CRSR 883.4K
- NRIX 739.8K
- Earning Date
- CRSR 05-06-2025
- NRIX 07-10-2025
- Dividend Yield
- CRSR N/A
- NRIX N/A
- EPS Growth
- CRSR N/A
- NRIX N/A
- EPS
- CRSR N/A
- NRIX N/A
- Revenue
- CRSR $1,348,872,000.00
- NRIX $56,417,000.00
- Revenue This Year
- CRSR $14.40
- NRIX $15.43
- Revenue Next Year
- CRSR $9.76
- NRIX N/A
- P/E Ratio
- CRSR N/A
- NRIX N/A
- Revenue Growth
- CRSR N/A
- NRIX N/A
- 52 Week Low
- CRSR $5.60
- NRIX $8.18
- 52 Week High
- CRSR $13.02
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- CRSR 59.51
- NRIX 54.08
- Support Level
- CRSR $7.91
- NRIX $9.67
- Resistance Level
- CRSR $9.21
- NRIX $10.79
- Average True Range (ATR)
- CRSR 0.38
- NRIX 0.53
- MACD
- CRSR 0.08
- NRIX 0.16
- Stochastic Oscillator
- CRSR 67.67
- NRIX 89.61
About CRSR Corsair Gaming Inc.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.